Flatiron Health Announces Research to Be Presented at American Society of Clinical Oncology 2024 Annual Meeting

Flatiron Health today announced its significant presence at this year's American Society of Clinical Oncology (ASCO) Annual Meeting, to be held in Chicago this June. Nine abstracts led by Flatiron have been accepted for poster presentation and online publication. A comprehensive of all accepted research using Flatiron data is available via ASCO's website.

Aligned with the conference theme, 'The Art and Science of Cancer Care: From Comfort to Cure,' Flatiron is dedicated to spearheading evidence generation in oncology. This year's accepted research reflects that dive into critical touch points across the oncology ecosystem.

"At Flatiron, we're pioneering new approaches to address health equity, enhance clinical trials, and bridge the gap between routine care and research," stated Neal Meropol, VP of Research Oncology, Flatiron Health. "Through innovative methodologies and real-world evidence, we're generating insights to improve cancer treatment and care delivery on behalf of patients. By seamlessly integrating science, technology, and medicine, we aim to deliver impactful results in collaboration with our partners."

This year's accepted abstracts once again showcase Flatiron's commitment to collaboration and partnership in pursuit of its mission to improve and extend lives by learning from the experience of every person with cancer.

Highlights include:

• A study employing machine-learning models across a nationwide cohort to explore practice patterns in the face of chemotherapy shortages.
• A study exploring the role of biomarkers in guiding treatment for metastatic breast cancer, focusing specifically on patients with HR+/HER2- tumors.
• A study examining how structural racism and social determinants of health contribute to inequities in endometrial cancer care, particularly among patients with advanced disease.

Schedule a meeting with Flatiron Health at ASCO 2024, and learn more about our abstracts and events, including workshops and panels.

Follow Flatiron Health on Twitter and LinkedIn for more updates and visit us in person at Booth #11123.

Poster Presentations

Impact of carboplatin and cisplatin shortages on treatment patterns in patients with metastatic solid tumors
Emily Castellanos, Qianyu Yuan, Niquelle Brown Wadé, Khilna Patel, Catherine Rinaldi, Samantha Reiss, Eunice Hankinson, Aaron Cohen, Melissa Estevez
Abstract #: 11149
Poster Bd #: 344

Real-world ctDNA testing patterns, associated biomarkers and sites of metastasis in early stage colorectal cancer
Erin Fidyk, Laurynas Kalesinskas, Konstantin Krismer, Auriane Blarre, Lilia Bouzit, John Ritten, Anca Marinescu, Jonathan Kelly, Katherine Harrison, Aaron Cohen
Abstract #: 3610
Poster Bd #: 273

Testing patterns and prevalence of PIK3CA, AKT1, and PTEN alterations among patients with HR+/HER2- metastatic breast cancer in the US
Partners: AstraZeneca, Biometrics Oncology, MD Anderson Cancer Center
Leak Park, Samantha Thompson, James Roose, Yichen Lu, Moumita Chaki, Clara Lam, J. Bryan Lorgulescu
Abstract #: 1041
Poster Bd # 19

Racial/ethnic inequities in care for patients with advanced endometrial cancer: what's structural racism and social determinants of health got to do with it?
Cleo A. Ryals, Gene G. Ho, Khilna Patel, Amy Pierre, Mustafa S. Ascha, Taavy A. Miller, Olive Mbah
Abstract #: 1602
Poster Bd #: 473

The BEV1L study: do real-world outcomes associated with the addition of bevacizumab to first-line chemotherapy in patients with ovarian cancer reinforce clinical trial findings?
Partners: GSK and University of Virginia
Linda Duska, Jonathan Lim, Tirza Areli Calderón Boyle, Mark Guinter, Siobhan Halloran, John Hartman, Jeanne M. Schilder, Jean A. Hurteau, Amanda Golembesky
Abstract #: 5563
Poster Bd #: 434

Real-world treatment patterns and outcomes by mismatch repair/microsatellite instability (MMR/MSI) status in patients with advanced endometrial cancer, 2018-2023
Partners: AstraZeneca, YU Langone Health, and Washington University School of Medicine
Premal H.Thaker, Bhavana Pothuri, Olga Tymejczyk, Samantha Reiss, Giovanni Nitti, Theresa Cain, Manila Hada
Abstract #: 5601
Poster Bd #: 472

Online Publications

Utility of automated data transfer for cancer clinical trials
Partners: MD Anderson and Washington University in St. Louis
Ivy Altomare, Addison Shelley, Yichen Lu, Paul Salcuni, Nicole Graves, Abhishek Maiti, Ramaswamy Govindan
Abstract: e23011

Characterization of cancer clinical trials in the community setting
Partners: ACCC, City of Hope, and Penn Lancaster
Ivy Altomare, Yichen Lu, Sumanta Pal, Leigh Boehmer, Latha Shivakumar, Lyndsey Griffin, Kimberly Demirhan, Molly Kisiel, Randall Oyer
Abstract #: e13506

Treatment inequities in patients with metastatic non-small cell lung cancer harboring actionable driver oncogenes in the first-line setting
Partners: Flatiron Health, Foundation Medicine, Genentech, Mary Bird Perkins Cancer Center, New York Cancer and Blood Specialists, OneOncology, Tennessee Oncology, and West Cancer Center and Research Institute
Gregory Vidal, Thomas Stricker, Esprit Ma, Elaine Yu, Zhiyu Xia, Daniel Sheinson, Murat Sincan, Richard Huang, Victor Lin, Richard Zuniga, Neha Jain, Richard Martin, Davey Daniel
Abstract #: e13673

About Flatiron Health

Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients' real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group. Flatiron.com @FlatironHealth